AstraZeneca PLC Release: Final Overall Survival Analysis of CONFIRM Shows a 4.1 Month Difference in Median Overall Survival When Using FASLODEX® (fulvestrant) Injection 500 mg Compared With 250 mg.1,2

WILMINGTON, Del.--(BUSINESS WIRE)--Today, updated overall survival (OS) data for FASLODEX® (fulvestrant) Injection in patients with hormone receptor-positive advanced breast cancer whose disease progressed or recurred following prior endocrine therapy was presented at the 35th CTRC-AACR San Antonio Breast Cancer Symposium by the principal investigator, Angelo Di Leo, MD, Head of the Sandro Pitigliani Medical Oncology Unit.1,2,3. The final updated CONFIRM OS, performed at 75% maturity (after a minimum follow up duration of 50 months), showed a 19% relative reduction in the risk of death (hazard ratio (HR) 0.81; 95% confidence interval [CI] 0.69-0.96). No adjustments were made for multiplicity, therefore these data cannot be considered statistically significant. The median OS for FASLODEX 500 mg and 250 mg was 26.4 months and 22.3 months, respectively.2